Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Myung-Ho | - |
dc.contributor.author | El-Gamal, Mohammed I. | - |
dc.contributor.author | Abdel-Maksoud, Mohammed S. | - |
dc.contributor.author | Sim, Taebo | - |
dc.contributor.author | Yoo, Kyung Ho | - |
dc.contributor.author | Oh, Chang-Hyun | - |
dc.date.accessioned | 2024-01-20T14:31:14Z | - |
dc.date.available | 2024-01-20T14:31:14Z | - |
dc.date.created | 2022-01-10 | - |
dc.date.issued | 2012-07-01 | - |
dc.identifier.issn | 0960-894X | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/129075 | - |
dc.description.abstract | A new series of diarylureas and diarylamides possessing 1H- pyrrolo[3,2-c]pyridine scaffold was designed and synthesized. Their in vitro antiproliferative activities against A375P human melanoma cell line and NCI-9 human melanoma cell line panel were tested. All the target compounds, except three amino derivatives 8g, h and 9h, demonstrated superior potencies against A375P to Sorafenib. In addition, compounds 8a and 9b-f demonstrated higher potencies than Vemurafenib against A375P. Compounds 8c and 9b were 7.50 and 454.90 times, respectively, more selective towards A375P melanoma cells over NIH3T3 fibroblasts. Furthermore, compounds 8d, e and 9a-d, f demonstrated very high potencies against the nine tested melanoma cell lines at the NCI. The bisamide derivatives 9a-c, f showed 2-digit nanomolar IC50 values over different cell lines of the NCI-9 melanoma cell lines. (C) 2012 Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.publisher | Pergamon Press Ltd. | - |
dc.subject | DIARYLAMIDES | - |
dc.subject | DIARYLUREAS | - |
dc.subject | SORAFENIB | - |
dc.subject | DIAGNOSIS | - |
dc.subject | THERAPY | - |
dc.title | Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines. Part 2 | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.bmcl.2012.05.004 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | Bioorganic & Medicinal Chemistry Letters, v.22, no.13, pp.4362 - 4367 | - |
dc.citation.title | Bioorganic & Medicinal Chemistry Letters | - |
dc.citation.volume | 22 | - |
dc.citation.number | 13 | - |
dc.citation.startPage | 4362 | - |
dc.citation.endPage | 4367 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000305278100030 | - |
dc.identifier.scopusid | 2-s2.0-84862170286 | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | DIARYLAMIDES | - |
dc.subject.keywordPlus | DIARYLUREAS | - |
dc.subject.keywordPlus | SORAFENIB | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | Pyrrolo[3,2-c]pyridine | - |
dc.subject.keywordAuthor | A375P | - |
dc.subject.keywordAuthor | Antiproliferative activity | - |
dc.subject.keywordAuthor | Melanoma | - |
dc.subject.keywordAuthor | Diarylurea | - |
dc.subject.keywordAuthor | Diarylamide | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.